The U.S. Food and Drug Administration (FDA) approved inebilizumab on June 11, 2020.

The U.S. Food and Drug Administration (FDA) approved Oriahnn on May 29, 2020.

The U.S. Food and Drug Administration (FDA) approved Tauvid on May 28, 2020.

The U.S. Food and Drug Administration (FDA) approved Phexxi on May 22, 2020.

Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.

The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.

The U.S. Food and Drug Administration (FDA) approved Selpercatinib on May 8, 2020, under an accelerated approval process.

The FDA granted approval for capmatinib on May 6, 2020. Capmatinib is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed with surgery.

The FDA approved Darzalex Faspro for the treatment of multiple myeloma and light chain amyloidosis in adults on May 1, 2020.

The FDA approved Bafiertam for the treatment of relapsing forms of multiple sclerosis (MS) on April 28, 2020.

MenQuadfi, a meningococcal conjugate vaccine, is FDA approved. The FDA granted approval for MenQuadfi on April 23, 2020.

Trodelvy (sacituzumab govitecan-hziy) received accelerated approval on April 22, 2020, for the treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) in adults who have received at least two prior therapies for metastatic disease.